Results 141 to 150 of about 101,286 (277)

Multifunctional tumor vaccines carrying thalidomide regulate T cell exhaustion and ferroptosis for immunotherapy strategies

VIEW, EarlyView.
MTV can greatly achieved antigen presenting cell (APCs), and THA will be released from the polyplex core and enhanced antigen presenting, thereby prompting APC maturation and antigen presenting. The membrane antigens on MTV are degraded into small peptides by proteasomes and presented by MHC complexes.
Anmin Huang, Ting Li, Ying Zhou, Sihang Li, Jian Zhang, Yingchao Li, Shijia Wu, Yifan Kong, Zhijie Yu, Jinglin Xia   +9 more
wiley   +1 more source

Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single‐Center Retrospective Study

The Journal of Dermatology, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for malignant melanoma (MM). However, given variable response rates and potential toxicities, identifying robust biomarkers is crucial. We investigated whether the modified Glasgow Prognostic Score (mGPS) predicts treatment efficacy and toxicity in Asian patients with
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara   +4 more
wiley   +1 more source

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Are two drugs better than one in advanced NSCLC? ABSTRACT Background Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC).
Junipearl Cheng, Charlotte McKay, Victoria Bray, Po Yee Yip, Annette Tognela, Peey Sei Kok   +5 more
wiley   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source

Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients

Australasian Journal of Dermatology, EarlyView.
ABSTRACT There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement ...
Sophie Walter, Francesca Watts, Raquel Ruiz Araujo, Thevaki Wain, Amanda Glanz, Diona Damian, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Linda K. Martin   +9 more
wiley   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

Cancer
Luo J, Li Z, Ge J, Cai S, Mo X, Liu W, Gui C, Du Q, Liu J.   +8 more
europepmc   +1 more source

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma

Alimentary Pharmacology &Therapeutics, EarlyView.
Patients who received immune checkpoint inhibitors before liver transplant for the treatment of hepatocellular carcinoma had rejection and survival outcomes comparable to those without ICI exposure. Most rejection episodes were effectively managed with medical therapy.
L. Aceituno, C. Magyar, P. Tabrizian, R. Marino, K. Watt, D. Chascsa, G. Schnickel, V. Banz, F. Alconchel, Celia Martagon, C. Moctezuma, T. Baker, C. Nwaduru, F. J. Krendl, R. Oberhuber, L. Ruiz‐Ortega, C. Demers, R. Bucur, G. O'Kane, A. Vogel, B. Mínguez, G. Sapisochin   +21 more
wiley   +1 more source

Nivolumab and bevacizumab attenuate cisplatin-induced hepatic inflammation and apoptosis in rats. [PDF]

Hepatol Forum
Karhan O, Turedi S.
europepmc   +1 more source